

Registered Office:

815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA). **Ph.**: +91-265-2991021 / 2991022

Email: admin@pardrugs.com

CIN No.: L24117GJ1999PLC035512

www.**pardrugs**.com

PAR/CS/NSE/2023-24/34

To,

Date:28/10/2023

The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

Subject: Disclosure of Related Party Transaction pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref.: Symbol- PAR, ISIN: INE04LG01015

Dear Sir/Madam,

Maharashtra

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), 2015, please find enclosed herewith disclosure of Related Party Transaction on standalone basis for the First half year ended 30<sup>th</sup> September, 2023 in the format as specified in the Circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021 by SEBI.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

For PAR DRUGS AND CHEMICALS LIMITED

(Sanket B. Trivedi)

Company Secretary & Compliance Officer

**Encl: As above** 



											Additional disclosure of rela	ated party transactions - applicable	only in case the related p	arty transaction relates t	o loans, inter-corporate deposits period when such transact		s made or given by the li	sted entity/subsidiary. The	se details need to be disclosed only once	e, during the repor
	Details of the party (listed entity /subsidiary) entering into the	Details of the counterparty			Value of the related		Value of transaction	In case monies are due to either party as a result of the transaction		In case any financial indebtadness is incurred to make as rive loans, inter-corporate danneits, advances or										
Sr No.	transaction	Details of the counterparty									investments				Details of the loans, inter-corporate deposits, advances or investments					
	Name PAN	ne PAN Name PAN	Relationship of the counterparty with the listed entity or its subsidiary	transaction	Details of other related party transaction	party transaction as approved by the audit committee	Remarks on approval by audit committee	during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan, issuance of debt/ any other etc.)	/ Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
А	Delete																			
1	Par Drugs And Chemicals Limited	Falgunbhai V Savani	Managing Director	Remuneration			Nil	25.7	2.79	2.89										1
2	Par Drugs And Chemicals Limited	Falgunbhai V Savani	Managing Director	Any other transaction	Director Sitting Fees		Nil	0.1	0.00	0.00										2
	Par Drugs And Chemicals Limited	Jigneshbhai V Savani	Director & CEO	Remuneration			Nil	25.7	3.09	3.14										3
	Par Drugs And Chemicals Limited	Jigneshbhai V Savani	Director & CEO	Any other transaction	Director Sitting Fees		Nil	0.0	0.00	0.00										4
	Par Drugs And Chemicals Limited	Ghanshyambhai B Savani	Whole-Time Director	Remuneration			Nil	25.7	3.19	3.24										5
	Par Drugs And Chemicals Limited	Ghanshyambhai B Savani	Whole-Time Director	Any other transaction	Director Sitting Fees		Nil	0.00	0.00	0.00										6
	Par Drugs And Chemicals Limited	Sanket Bhupendrabhai Trivedi	Company Secretary	Remuneration			Nil	2.2	0.43	0.48										7
	Par Drugs And Chemicals Limited	Chintan Prataphhai Chauhan	Chief Financial Officer	Remuneration			Nil	2.0	0.36	0.40										8
	Par Drugs And Chemicals Limited	Naynaben J Savani	Non-Executive Director	Any other transaction	Director Sitting Food		ANI	2.0	0.00	0.40										9
	Par Drugs And Chemicals Limited	Kajal Chitanbhai Vaghani	Independent Director	Any other transaction			ANI	0.11	0.00	0.10										10
		Krishna Mitulbhai Shah	Independent Director				AVI	0.1	0.0.	0.10										11
	Par Drugs And Chemicals Limited			Any other transaction			NII	0.1	0.05	0.10										12
	Par Drugs And Chemicals Limited	Pravin Manjibhai Bhayani	Independent Director	Any other transaction			NII	0.1	0.05	0.10										13
	Par Drugs And Chemicals Limited		Independent Director Karta Wholetime Director	Any other transaction			Nil	0.0	0.05	0.05										14
	Par Drugs And Chemicals Limited		Karta Promoter, Chairman	Purchase of fixed assets			Nil	76.9		0.00										15
15	Par Drugs And Chemicals Limited	Savani Falgun Vallabhbhai HUF Savani Jigneshkumar Vallabhbhai	& Managing Director Karta Promoter, Director &	Purchase of fixed assets			Nil	76.9	0.00	0.00							-			15
16	Par Drugs And Chemicals Limited	HUF	CEO	Purchase of fixed assets			Nil	76.9	0.00	0.00										16
17	Par Drugs And Chemicals Limited	Savani Prathambhai Ghanshyambhai	Son of Whole-Time Director	Remuneration			AICI	1.31	0.00	0.22										17

Text Block							
Textual Information(1)	By considering recommendations of Audit Committee & Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved increase in remuneration of respective director for a period of 2 years from 26th Day of November, 2021 to 25th Day of November, 2023, Subsequently the same is approved by the shareholders in the Twenty Second (22nd )Annual General Meeting (AGM) of the Members of Par Drugs And Chemicals Limited which was held on Wednesday, 29th Day of September, 2021						
Textual Information(2)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board an committee meeting for all director.						
Textual Information(3)	By considering recommendations of Audit Committee & Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved increase in remuneration of respective director for a period of 2 years from 26th Day of November, 2021 to 25th Day of November, 2023, Subsequently the same is approved by the shareholders in the Twenty Second (22nd )Annual General Meeting (AGM) of the Members of Par Drugs And Chemicals Limited which was held on Wednesday, 29th Day of September, 2021						
Textual Information(4)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.						
Textual Information(5)	By considering recommendations of Audit Committee & Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved increase in remuneration of respective director for a period of 2 years from 26th Day of November, 2021 to 25th Day of November, 2023, Subsequently the same is approved by the shareholders in the Twenty Second (22nd )Annual General Meeting (AGM) of the Members of Par Drugs And Chemicals Limited which was held on Wednesday, 29th Day of September, 2021						
Textual Information(6)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.						
Textual Information(7)							
Textual Information(8)							
Textual Information(9)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.						
Textual Information(10)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.						
Textual Information(11)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.						
Textual Information(12)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.						
Textual Information(13)	By considering recommendations of Audit Committee and Nomination and Remuneration Committee, the Board at its meeting held on 24th August, 2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.						
Textual Information(14)	Audit committee held on 27.04.2023 discussed and approved the transaction with respect to purchase new land admeasuring 24285.00 Square meter for the future expansion of Company from the related parties at arms length basis. Which is not material related party transaction as per SEBI (LODR)Regulations,2015.						
Textual Information(15)	Audit committee held on 27.04.2023 discussed and approved the transaction with respect to purchase new land admeasuring 24285.00 Square meter for the future expansion of Company from the related parties at arms length basis. Which is not material related party transaction as per SEBI (LODR)Regulations,2015.						
Textual Information(16)	Audit committee held on 27.04.2023 discussed and approved the transaction with respect to purchase new land admeasuring 24285.00 Square meter for the future expansion of Company from the related parties at arms length basis. Which is not material related party transaction as per SEBI (LODR)Regulations,2015.						
Textual Information(17)	Audit committee held on 27.04.2023 discussed and approved the transaction.						